Suchergebnisse - "Cao, Junning"

PubPharm (118)

1

Integrated Single Cell Analysis Reveals An Atlas of Tumor Associated Macrophages in Hepatocellular Carcinoma

enthalten in: Inflammation | 2024

von Li, X. | Li, R. | Miao, X. | +6

2

Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score : A retrospective cohort study

enthalten in: Heliyon | 2024

von Chen, G. | Guo, P. | Wang, J. | +4

3

Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors

enthalten in: Haematologica | 2024

von Song, Y. | Cao, J. | Zhang, Q. | +25

4

Method of learning artificial neural network for detecting prostate cancer from TURP pathology image and computing system for performing method

enthalten in: Europäisches Patentamt | 2024

von CAO JUNNING | ZHANG HUAYUN | KWAK TAE-YOUNG | +1

5

Long-term survival and portal vein patency with novel PVTT surgery approach in advanced HCC patients with Vp3/4 PVTT following combination therapy of TKIs and PD-1 inhibitors

enthalten in: BMC surgery | 2023

von Jiao, T. | Tang, H. | Zhang, W. | +8

6

Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors : A Phase I Trial

enthalten in: The oncologist | 2023

von Cao, J. | Guo, H. | Ji, D. | +8

7

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma : A phase 2, multicenter, open-label study

enthalten in: American journal of hematology | 2023

von Deng, L. | Li, Z. | Zhang, H. | +30

8

China Anti-Cancer Association (CACA) guidelines for holistic integrative management of lymphoma (version 2022)

enthalten in: Holistic integrative oncology | 2023

von Zhang, Q. | Feng, J. | Wang, H. | +24

9

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma : a single-arm, phase II trial

enthalten in: Journal for immunotherapy of cancer | 2023

von Zhang, W. | Tong, S. | Hu, B. | +22

10

Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma : an open-label phase II study (Gxplore-003)

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Shi, Y. | Cui, J. | Zhou, H. | +16

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]